Evelo Biosciences, Inc.(Nasdaq: EVLO) (“Evelo”), a biotechnology company developing monoclonal microbials, a new modality of oral biologic medicines, announced that the University of Chicago has dosed the first patient in an investigator-sponsored Phase 2a clinical […]
Second Genome, Inc., a clinical-stage company focused on the development of novel therapeutics identified through microbiome science, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating SGM-1019 for […]
One month short of its official 145th anniversary, global bioscience company Chr. Hansen is ranked the most sustainable company in the world by Corporate Knights, a specialized Toronto-based media and investment research firm. This was […]
Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women’s health and gastroenterology. The collaboration brings together specialist expertise […]
Bioharmony Therapeutics, Inc. (“Bioharmony”), a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, announced today that it has entered into a Collaborative Research and Licensing Agreement with Boehringer […]
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced the appointment of Eric D. Shaff as President and Chief Executive Officer. Mr. Shaff, who is currently Chief Operating and Financial Officer, succeeds Roger J. Pomerantz, M.D. Mr. Shaff […]
The new blood test, sclero-smart™, measures levels of anti-vinculin, recently found to be elevated in patients with scleroderma and associated with gastrointestinal complications. This suggests a link between scleroderma and the gut microbiome, a finding […]
A systematic review and meta-analysis was recently published in the World Journal of Clinical Cases1 that asses the effects of probiotic preparation Medilac-S® (Enterococcus faecium Rosell®-26 and Bacillus subtilisRosell®-179), as adjunctive therapy in ulcerative colitis […]
OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, announced that it has entered into definitive agreements to acquire CoreBiome. The transactions are expected to close […]
4D pharma plc (AIM: DDDD) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D’s Live Biotherapeutic oncology pipeline across a range of cancer settings. The alliance brings […]
In just a few short years, Rebiotix has taken the concept of “bugs as drugs” and turned it into actual practice, constructing a standardized, stabilized drug product from the broad consortia of microbes present in a […]